



To whom it may concern



February 16, 2026

Company Name: Y.A.C. Holdings Co., Ltd.
Representative: Takefumi Momose,
Chairman and President
(Code No. 6298
Tokyo Stock Exchange Prime)
Inquiries: Takao Murasawa
General Manager
of Corporate Business Dept.
(Tel: +81-42-546-1161)

Announcement of a Basic Agreement on Collaboration with GLOME Holdings, Inc. in the Field of Autism Spectrum Disorder (ASD) Utilizing Hair Analysis Technology

We are pleased to announce that we have reached a basic agreement with GLOME Holdings, Inc. (hereinafter referred to as "GLOME HD") regarding the fundamental principles and future direction of our collaboration. This collaboration aims to advance initiatives in the medical and healthcare fields that support early identification and intervention in the area of Autism Spectrum Disorder (ASD).

1. Background and Purpose of the Collaboration

Autism Spectrum Disorder (ASD) requires an environment that facilitates early recognition and appropriate support, and there is a growing need for effective approaches to providing useful information to individuals with ASD, their families, and supporters.

Within our group, we have been advancing initiatives to deliver scientifically grounded analytical information by leveraging our world-unique hair-cutting robotics technology and the hair-based biological analysis technology of our partner, LINUS BIOTECHNOLOGY, INC.

Meanwhile, GLOME HD has an extensive track record of providing business support to medical institutions and healthcare-related organizations in the medical and healthcare sectors.

Through this collaboration, our company and GLOME HD aim to create new social value in the field of Autism Spectrum Disorder (ASD) by combining the technological and business foundations that each party has cultivated.

2. Overview of the Collaboration

- Joint examination of approaches to information provision and support in the Autism Spectrum Disorder (ASD) field, such as early identification and pathways to consultation, utilizing hair analysis technology (excluding data analysis information).
- Consideration of implementation models leveraging networks in the medical and healthcare fields
※Operational activities related to this collaboration will be carried out by our subsidiary, YAC Bio Inc.

3. Future Outlook and Impact on Performance

Based on this Agreement, our company and GLOME HD will proceed with discussions on the specific initiatives to be undertaken.

At present, we expect the impact of this matter on the business performance of our group to be minimal. Should any matters arise in the future that require disclosure, we will make an announcement promptly.

(GLOME HD Overview)

Company Name	GLOME Holdings, Inc.
URL	https://glome-holdings.com/
Address	Ark Mori Building 31F, 1-12-32 Akasaka, Minato-ku, Tokyo, 107-6031
Representative	Masazumi Sugahara, President & Chief Executive Director
Date of foundation	June, 1987
Capital	3,049,316,700 yen